Emergent BioSolutions Inc. (NYSE: EBS) announces it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-closing adjustments. With the transaction closed, Bora has acquired the assets, equipment, and workforce associated with the 87,000 square foot Baltimore-Camden manufacturing facility.
Read the full article: Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2024/08/20/2933034/33240/en/Emergent-BioSolutions-Finalizes-Sale-of-Baltimore-Camden-Manufacturing-Site-to-Bora-Pharmaceuticals.html